Teva Pharmaceutical Industries

Forecast & Rating13 analysts currently cover Teva Pharmaceutical Industries, with about 92.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $41.40, about 13.5% upside from the current price of $36.46. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 76.6% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Teva Pharmaceutical Industries closely still see room for the stock to rise. Data as of Aug 11, 2026; for reference only and not investment advice.